Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. In ...

Among patients with diabetic kidney disease (DKD), those with anemia may especially reap cardiovascular benefits from finerenone treatment. Finerenone treatment reduces cardiovascular and kidney risks ...

Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Diabetic Kidney Disease (DKD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an ...

Please provide your email address to receive an email when new articles are posted on . Topline findings from the FIDELIO-DKD study show the investigational drug finerenone delayed the progression of ...

—Youth-onset T2D carries a higher risk of diabetic kidney disease than both adult-onset T2D of similar duration and T1D. Is there a path to prevention and slowing progression? The leading cause of end ...

Considerations for the benefit shown in combining finerenone with SGLT2 inhibitors in patients with type 2 diabetes and CKD. Rajiv Agarwal, MD, MS: The SGLT2 inhibitors are an absolutely amazing class ...

Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...

Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial. C. Ola Landgren, MD, PhD: The once-weekly and twice-weekly ...

DKD Energy specializes in commercial and residential solar installations. Service areas extend across parts of Texas. Solar panel costs vary based on your location and other factors. The map below ...

BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership, has announced the launch of a 5-year project with the aim to improve prevention and management ...

In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its Phase II pipeline for diabetic kidney disease (DKD). The objective of the Phase IIb study was to evaluate the ...